Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9607 posts found.

index_ph001

Daiichi Sankyo show positive results for atrial fibrillation treatment Lixiana

March 18, 2019 Manufacturing and Production, Research and Development Daiichi Sankyo, Lixiana, pharma, vitamin K antagonist

Japanese firm Daiichi Sankyo has announced positive results of the first randomised controlled trial of uninterrupted Lixiana (edoxoban) in atrial …
News
mme_fb_event_banner_tangent_dj

Patient Experience: Living with two rare diseases

March 18, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Wyburn-Mason Syndrome, acromegaly, feature, patient experience, pharma, rare disease

Dan Jeffries was diagnosed with the ultra-rare condition Wyburn-Mason syndrome at a young age, leaving him blind in one eye. …
Feature
shutterstock_212432119

Allergy Therapeutics’ adjuvanted birch allergoid drug shocks with Phase 3 failure

March 18, 2019 Research and Development, Sales and Marketing allergy, allergy therapeutics, pharma, trial failure

UK-based biotech firm Allergy Therapeutics has been left disappointed after it became evident that its adjuvanted birch allergoid product failed …
News
heart-2372134_640

Sanofi and Regeneron’s Praluent approved in Europe to reduce CV risk

March 18, 2019 Research and Development, Sales and Marketing Regeneron, Sanofi, cardiovascular, heart, praluent

Sanofi and Regeneron’s Praluent (alirocumab) has been awarded approval by the European Commission, it has emerged, as a therapy to …
News
mr058666-web

Merck KGaA enters drug discovery partnership with AI firm Itkos

March 15, 2019 Medical Communications, Research and Development AI, Merck, Merck KGaA, drug discovery, pharma

Merck KGaA and artificial intelligence (AI) firm Iktos have entered into a partnership, the pair have announced, to leverage the …
News
norman_sharpless_official_photo

National Cancer Institute Director Ned Sharpless to become interim FDA Commissioner

March 15, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Following the surprise resignation of current FDA Commissioner Dr Scott Gottlieb a week earlier, Dr Norman ‘Ned’ Sharpless, Director of …
Appointment
richard-francis-big-image_0

Sandoz CEO Richard Francis to step down

March 15, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Richard Francis is set to step down his role as Chief Executive of Novartis’ generics arm Sandoz after five years’ …
Appointment
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

March 15, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Acadia Pharmaceuticals, FDA, Sandoz, brexit, genomics, pharma, pharmacovigilance, top 10

The US Department of Justice has launched an investigation into the sales and marketing practices of San Diego firm Acadia …
News
celgene_building

Celgene’s Abraxane combo flops in phase 3 cancer trials

March 14, 2019 Research and Development Abraxane, Celgene, clinical trials, pharma, trials

Celgene’s Abraxane, in combination gemcitabine, has failed to meet its primary endpoint in a pivotal Phase 3 trial of patients …
News
ent-cholesterol_molecule_spacefill

New class of drugs offer alternative to statins

March 14, 2019 Research and Development cholesterol, health, imperial college london, research, statins

A new class of cholesterol lowering drugs may help patients who are unable to take statins, according to a study …
News
richard-francis-big-image

Sandoz CEO Richard Francis to step down

March 14, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Novartis, Sandoz, appointment, pharma

Richard Francis is set to step down his role as Chief Executive of Novartis’ generics arm Sandoz after five years’ …
News
norman_sharpless_official_photo

National Cancer Institute Director Ned Sharpless to become interim FDA Commissioner

March 13, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Ned Sharpless, Scott Gottlieb, appointment, pharma

Following the surprise resignation of current FDA Commissioner Dr Scott Gottlieb a week earlier, Dr Norman ‘Ned’ Sharpless, Director of …
News
janssen_latest_logo_on_sign_closer

Janssen’s ulcerative colitis treatment shows positive results in phase 3 trials

March 13, 2019 Manufacturing and Production, Research and Development Jansenn, Stelara, phase 3 trials, ulcerative colitis

Janssen’s ulcerative colitis treatment, Stelara (ustekinumab subcutaneous) has shown positive results as maintenance therapy in phase 3 trials. The study …
News
lilly_building_with_american_flag_web

Lilly’s Cyramza hits Phase 3 endpoint in first-line metastatic lung cancer treatment

March 13, 2019 Research and Development Cancer, Eli Lilly, cyramza, lung cancer, pharma

Eli Lilly’s vascular endothelial growth factor (VEGF) Receptor 2 antagonist Cyramza (ramucirumab) has succeeded in hitting its primary endpoint at …
News
28246711066_52e38bc591_z

Healthcare industry could take up to five years to stabilise after no-deal Brexit

March 13, 2019 Manufacturing and Production, Medical Communications, Research and Development GlobalData, analysis, brexit, no-deal Brexit, surveys

The healthcare industry could take up to five years to stabilise in the event of a no-deal Brexit, according to …
News
The Gateway to Local Adoption Series

Latest content

Secarna appoints Jens Holstein and Richard Mark Engelhard to new Advisory Board

March 25, 2026

Roche adds 2,176 NVIDIA Blackwell GPUs to its hybrid-cloud AI factory

March 25, 2026

ReproNovo appoints Mark Altmeyer as Chairman of the Board

March 24, 2026

EndoCyclic New Drug application approved by US FDA for endometriosis treatment

March 24, 2026

Mestag Therapeutics appoints Lindsey Rolfe as Chief Medical Officer and Pascal Merchiers as Chief Development Officer

March 23, 2026